Sciele Pharma Announces That the FDA Has Issued an Approvable Letter for the Head Lice Treatment Chiropractic Economics July 16, 2008 Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that the U.S. Food & Drug Administration (FDA) Related Posts Western States Chiropractic College announces new name Standard Process ushers in new era of innovation with Center of Excellence Author explains how technology can spread the chiropractic message Texas Chiropractic College welcomes new clinic dean GAO: CMS could be doing more under EHR program